Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT01349933 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

NIH

Sponsor class

Conditions

Recurrent Squamous Cell Carcinoma of the Nasopharynx
Stage IV Squamous Cell Carcinoma of the Nasopharynx

Interventions

DRUG: Akt inhibitor MK2206

Sponsor

National Cancer Institute (NCI)